Fig. 1.

Proportions of patients in the MEC and AC cohorts who experience no vomiting or moderate-to-severe nausea in the delayed phase, by risk and treatment groups. Low-risk patients were free from vomiting and moderate-to-severe nausea during the acute phase; high-risk patients experienced vomiting or moderate-to-severe nausea during the acute phase. Patients received palonosetron plus dexamethasone on day 1 either with or without dexamethasone on days 2 and 3. MEC moderately emetogenic chemotherapy, AC anthracycline plus cyclophosphamide, Dex dexamethasone